MASM
DFTX

MH & Associates Securities Management’s Definium Therapeutics DFTX Stock Holding History

MH & Associates Securities Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25K Hold
66
– – ﹤0.01% 90
2025
Q4 		$884 Buy
+66
New +$817 ﹤0.01% 98

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MH & Associates Securities Management's DFTX Position: Q1 2026 in Review

MH & Associates Securities Management held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 66 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #90.

MH & Associates Securities Management first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • MH & Associates Securities Management held 66 shares of Definium Therapeutics worth $1.25K as of Q1 2026.
  • MH & Associates Securities Management left its Definium Therapeutics share count unchanged in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of MH & Associates Securities Management's portfolio in Q1 2026, its #90 holding.
  • MH & Associates Securities Management first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on MH & Associates Securities Management's 13F filing for Q1 2026, filed 1 May 2026.